Genistein, a phytoestrogen, attenuates monocrotaline-induced pulmonary hypertension

Respiration

Volumn 73, Issue 1, 2006, Pages 105-112

  Homma, Noriyuki ^a   Morio, Yoshiteru ^a   Takahashi, Hideki ^a   Yamamoto, Akihito ^a   Suzuki, Tsutomu ^a   Sato, Koichi ^a   Muramatsu, Masashi ^a   Fukuchi, Yoshinosuke ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Endothelial nitric oxide synthase; Endothelin 1; Genistein; Monocrotaline; Pulmonary hypertension

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN 1; GENISTEIN; MONOCROTALINE; PHYTOESTROGEN;

ANIMAL TISSUE; ARTERIAL PRESSURE; ARTICLE; BRONCHIOLE; CATHETERIZATION; CONTROLLED STUDY; DOWN REGULATION; HEART RATE; HEART VENTRICLE HYPERTROPHY; HEMODYNAMIC PARAMETERS; LUNG ARTERY; LUNG HOMOGENATE; MALE; MEAN ARTERIAL PRESSURE; MORPHOLOGICAL TRAIT; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; RADIOIMMUNOASSAY; RAT; SOYBEAN; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; DOWN-REGULATION; ENDOTHELIN-1; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; GENISTEIN; HEMODYNAMIC PROCESSES; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; IMMUNOHISTOCHEMISTRY; LUNG; MALE; MONOCROTALINE; NITRIC OXIDE SYNTHASE; RATS; RATS, SPRAGUE-DAWLEY; VASCULAR RESISTANCE;

EID: 33644541826     PISSN: 00257931     EISSN: None     Source Type: Journal    
DOI: 10.1159/000088946     Document Type: Article

References (39)

1. Demoncheaux EAG, Higenbottam TW, Kiely DG, Wong JM, Wharton S, Varcoe R, Siddons T, Spivey AC, Hall K, Gize AP: Decreased whole body endogenous nitric oxide production in patients with primary pulmonary hypertension. J Vasc Res 2005;42:133-136.
2. Gianetti J, Bevilacqua S, De Caterina R: Inhaled nitric oxide: more than a selective pulmonary vasodilator. Eur J Clin Invest 2002;32:628-635.
3. Weinberger B, Laskin DL, Heck DE, Laskin JD: The toxicology of inhaled nitric oxide. Toxicol Sci 2001;59:5-16.
4. Abe K, Shimokawa H, Morikawa K, Uwatoku T, Oi K, Matsumoto Y, Hattori T, Nakashima Y, Kaibuchi K, Sueishi K, Takeshita A: Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats. Circ Res 2004;94:385-393.
5. Fagan KA, Oka M, Bauer NR, Gebb SA, Ivy DD, Morris KG, McMurtry IF: Attenuation of acute hypoxic pulmonary vasoconstriction and hypoxic pulmonary hypertension in mice by inhibition of Rho-kinase. Am J Physiol Lung Cell Mol Physiol 2004;287:L656-L664.
6. Hironaka E, Hongo M, Sakai A, Mawatari E, Terasawa F, Okumura N, Yamazaki A, Ushiyama Y, Yazaki Y, Kinoshita O: Serotonin receptor antagonist inhibits monocrotaline-induced pulmonary hypertension and prolongs survival in rats. Cardiovasc Res 2003;60:692-699.
7. Kanno S, Wu YJ, Lee PC, Billiar TR, Ho C: Angiotensin-converting enzyme inhibitor preserves p21 and endothelial nitric oxide synthase expression in monocrotaline-induced pulmonary arterial hypertension in rats. Circulation 2001;104:945-950.
8. Nishimura T, Faul JL, Berry GJ, Vaszar LT, Qui D, Pearl RG, Kao PN: Simvastatin attenuates smooth muscle neointimal proliferation and pulmonary hypertension in rats. Am J Respir Crit Care Med 2002;166:1403-1408.
9. Zhao YD, Campbell AI, Robb M, Ng D, Stewart DJ: Protective role of angiopoietin-1 in experimental pulmonary hypertension. Circ Res 2003;92:984-991.
10. Filipeanu CM, Brailoiu E, Huhurez G, Slatineanu S, Baltatu O, Branisteanu DD: Multiple effects of tyrosine kinase inhibitors on vascular smooth muscle contraction. Eur J Pharmacol 1995;281:29-35.
11. Toma C, Jensen PE, Prieto D, Hughes A, Mulvany MJ, Aalkjaer C: Effects of tyrosine kinase inhibitors on the contractility of rat mesenteric resistance arteries. Br J Pharmacol 1995;114:1266-1272.
12. Kitayama J, Kitazono T, Ooboshi H, Ago T, Ohgami T, Fujishima M, Ibayashi S: Chronic administration of a tyrosine kinase inhibitor restores functional and morphological changes of the basilar artery during chronic hypertension. J Hypertens 2002;20:2205-2211.
13. Squadrito F, Altavilla D, Squadrito G, Saitta A, Cucinotta D, Minutoli L, Deodato B, Ferlito M, Campo GM, Bova A, Caputi AP: Genistein supplementation and estrogen replacement therapy improve endothelial dysfunction induced by ovariectomy in rats. Cardiovasc Res 2000;45:454-462.
14. Karamsetty MR, Klinger JR, Hill NS: Phytoestrogens restore nitric oxide-mediated relaxation in isolated pulmonary arteries from chronically hypoxic rats. J Pharmacol Exp Ther 2001;297:968-974.
15. Mishra SK, Abbot SE, Choudhury Z, Cheng M, Khatab N, Maycock NJR, Zavery A, Aaronson PI: Endothelium-dependent relaxation of rat aorta and main pulmonary artery by phytoestrogens genistein and daidzein. Cardiovasc Res 2000;46:539-546.
16. Nakazawa H, Hori M, Ozaki H, Karaki H: Mechanisms underlying the impairment of endothelium-dependent relaxation in the pulmonary artery of monocrotaline-induced pulmonary hypertensive rats. Br J Pharmacol 1999;128:1098-1104.
17. Resta TC, Gonzales RJ, Dail WG, Sanders TC, Walker BR: Selective upregulation of arterial endothelial nitric oxide synthase in pulmonary hypertension. Am J Physiol Heart Circ Physiol 1997;272:H806-H813.
18. Frasch HF, Marshall C, Marshall BE: Endothelin-1 is elevated in monocrotaline pulmonary hypertension. Am J Physiol 1999;276:L304-L310.
19. Jasmin JF, Cernacek P, Dupuis J: Activation of the right ventricular endothelin (ET) system in the monocrotaline model of pulmonary hypertension: response to chronic ETA receptor blockade. Clin Sci (Lond) 2003;105:647-653.
20. Mansoor AM, Honda M, Saida K, Ishinaga Y, Kuramochi T, Maeda A, Takabatake T, Mitsui Y: Endothelin induced collagen remodeling in experimental pulmonary hypertension. Biochem Biophys Res Commun 1995;215:981-986.
21. Mathew R, Zeballos GA, Tun H, Gewitz MH: Role of nitric oxide and endothelin-1 in monocrotaline-induced pulmonary hypertension in rats. Cardiovasc Res 1995;30:739-746.
22. Miyauchi T, Yorikane R, Sakai S, Sakurai T, Okada M, Nishikibe M, Yano M, Yamaguchi I, Sugishita Y, Goto K: Contribution of endogenous endothelin-1 to the progression of cardiopulmonary alterations in rats with monocrotaline- induced pulmonary hypertension. Circ Res 1993;73:887-897.
23. Sasaki S, Asano M, Ukai T, Nomura N, Maruyama K, Manabe T, Mishima A: Nitric oxide formation and plasma L-arginine levels in pulmonary hypertensive rats. Respir Med 2004;98:205-212.
24. Suhara H, Sawa Y, Fukushima N, Kagisaki K, Yokoyama C, Tanabe T, Ohtake S, Matsuda H: Gene transfer of human prostacyclin synthase into the liver is effective for the treatment of pulmonary hypertension in rats. J Thorac Cardiovasc Surg 2002;123:855-861.
25. Takahashi T, Kanda T, Inoue M, Sumino H, Kobayashi I, Iwamoto A, Nagai R: Endothelin converting enzyme inhibitor protects development of right ventricular overload and medial thickening of pulmonary arteries in rats with monocrotaline-induced pulmonary hypertension. Life Sci 1998;63:PL137-PL143.
26. Hanasato N, Oka M, Muramatsu M, Nishino M, Adachi H, Fukuchi Y: E-4010, a selective phosphodiesterase 5 inhibitor, attenuates hypoxic pulmonary hypertension in rats. Am J Physiol 1999;277:L225-L232.
27. Naruse M, Naruse K, Kurimoto F, Horiuchi J, Tsuchiya K, Kawana M, Kato Y, Zeng ZP, Sakurai H, Demura H, Shizume K: Radioimmunoassay for endothelin and immunoreactive endothelin in culture medium of bovine endothelial cells. Biochem Biophys Res Commun 1989;160:662-668.
28. Polkowski K, Mazurek AP: Biological properties of genistein. A review of in vitro and in vivo data. Acta Pol Pharm 2000;57:135-155.
29. Armitage M, Nooney J, Evans S: Recent concerns surrounding HRT. Clin Endocrinol (Oxf) 2003;59:145-155.
30. Dubey RK, Gillespie DG, Imthurn B, Rosselli M, Jackson EK, Keller PJ: Phytoestrogens inhibit growth and MAP kinase activity in human aortic smooth muscle cells. Hypertension 1999;33:177-182.
31. Pan W, Ikeda K, Takebe M, Yamori Y: Genistein, daidzein and glycitein inhibit growth and DNA synthesis of aortic smooth muscle cells from stroke-prone spontaneously hypertensive rats. J Nutr 2001;131:1154-1158.
32. Tsuda Y, Okazaki M, Uezono Y, Osajima A, Kato H, Okuda H, Oishi Y, Yashiro A, Nakashima Y: Activation of extracellular signal-regulated kinase is essential for pressure-induced proliferation of vascular smooth muscle cells. Eur J Pharmacol 2002;446:15-24.
33. Squadrito F, Altavilla D, Crisafulli A, Cucinotta D, Morabito N, D'Anna R, Corrado F, Ruggeri P, Frisina N, Squadrito G: Effect of genistein on endothelial function in postmenopausal women: a randomized, double-blind, controlled study. Am J Med 2003;114:470-476.
34. Tyler RC, Muramatsu M, Abman SH, Stelzner TJ, Rodman DM, Bloch KD, McMurtry IF: Variable expression of endothelial NO synthase in three forms of rat pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 1999;276:L297-L303.
35. Laplante MA, Wu R, El Midaoui A, de Champlain J: NAD(P)H oxidase activation by angiotensin II is dependent on p42/44 ERK-MAPK pathway activation in rat's vascular smooth muscle cells. J Hypertens 2003;21:927-936.
36. Mathew R, Yuan N, Rosenfeld L, Gewitz MH, Kumar A: Effects of monocrotaline on endothelial nitric oxide synthase expression and sulfhydryl levels in rat lungs. Heart Dis 2002;4:152-158.
37. Giaid A, Yanagisawa M, Langleben D, Michel RP, Levy R, Shennib H, Kimura S, Masaki T, Duguid WP, Stewart DJ: Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993;328:1732-1739.
38. Çelik G, Karabiyikoglu G: Local and peripheral plasma endothelin-1 in pulmonary hypertension secondary to chronic obstructive pulmonary disease. Respiration 1998;65:289-294.
39. Hill NS, Warburton RR, Pietras L, Klinger JR: Nonspecific endothelin-receptor antagonist blunts monocrotaline-induced pulmonary hypertension in rats. J Appl Physiol 1997;83:1209-1215.